RobertAlanFiglinMDFACP.(He/Him)

Genitourinary Oncology, Hematologic Oncology, Thoracic Cancer

Steven Spielberg Family Chair in Hematology-Oncology Professor, Biomedical Sciences Professor, Medicine Cedars-Sinai Medical Center Professor Emeritus, Medicine and Urology, David Geffen School of Medicine, UCLA Deputy Director, the Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center Deputy Director, Cedars-Sinai Cancer, Cedars-Sinai Health System, Los Angeles, CA

Join to view full profile

Dr. Figlin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Figlin's full profile

Already have an account?

Office
8700 Beverly Blvd.
N. Tower, LL, AC1085
Los Angeles, CA 90048
Phone+1 310-423-1331

Fax+1 310-248-6990

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1980 - 1982
Cedars-Sinai Medical CenterChief Residency, Internal Medicine, 1979 - 1980
Cedars-Sinai Medical CenterResidency, Internal Medicine, 1976 - 1979
MCP-Hahnemann College of MedicineClass of 1976

Certifications & Licensure

CA State Medical License 1977 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2007-2014
Top Doctors:LA Area Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2006-2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Vaccine Therapy in Treating Patients With Advanced Cancer Start of enrollment: 2000 Apr 01
Completed
Phase 1
Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer Start of enrollment: 2000 Dec 01
Completed
Phase 1
Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors
Completed
Phase 1, Phase 2
ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung Cancer
Unknown status
Phase 2
RPI.4610 in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2001 Sep 01
Completed
Phase 2
Epothilone B in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2002 Apr 01
Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2003 Aug 01
Completed
Phase 1
Docetaxel and Carboplatin With or Without Zoledronate in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2004 Aug 01
Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2005 Jul 01
Unknown status
Phase 2
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma Start of enrollment: 2012 Nov 01
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

147 citations
Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis.
Xiwei Wu, Lihong Weng, Xuejun Li, Chao Guo, Sumanta K. Pal
Plos One. 2012-05-18
2802 citations
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Gary R. Hudes, Michael A. Carducci, Piotr Tomczak, Janice P. Dutcher, Robert A. Figlin
The New England Journal of Medicine. 2007-05-31
42 citations
Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance.
Min Young Lee, Austin Yeon, Muhammad Shahid, Eunho Cho, Vikram Sairam
Oncotarget. 2018-01-13

Lectures

Interim data analysis of the ADAPT trial using the modified intent to treat (mITT) population re-evaluates Rocapuldencel-T for clinical benefit over standard of care.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Big Cancer Practice Acquisition Reflects Changing Oncology LandscapeOctober 25th, 2024
Oncologist Burnout: Will New ESMO Recommendations Actually Help?October 1st, 2024
After Practice Change in Unresectable Stage III NSCLC, Questions RemainSeptember 4th, 2024
Join now to see all

Grant Support

LATE Stage Lung CancerNational Cancer Institute2011
Cancer Center Support GrantNational Cancer Institute2007–2009
Oncology Research Career Development ProgramNational Cancer Institute2006–2007
Phase II Trial Of Recombinant Human Granulocyte MacropNational Center For Research Resources2004
Core--Clinical Research UnitNational Cancer Institute1994–2002
Trial Of Pegylated Interferon A2A In Renal Cell CancerNational Center For Research Resources2001
Safety And Biologic Activity Of Rhu GM-CSF And Rhu IL4 To Treat CancerNational Center For Research Resources1999–2001
Antigen Specific Immunotherapy In MUC 1 Positive PatientsNational Center For Research Resources1999–2001
Ucla/Jccc--Southwest Oncology GroupNational Cancer Institute1998–2000
Phase I Trial To Determine The Safety And Biologic Activity Of Rhu GM-CSFNational Center For Research Resources1998
Randomized Study Of Pegylated Recombinant Human Megakaryocyte GrowthNational Center For Research Resources1996–1997
Southwest Oncology GroupNational Cancer Institute1993–1997
Preliminary Efficacy Of IV ATP Treatment Of Lung CancerNational Center For Research Resources1996